The results of the present study are in line with the results of a meta-analysis of clinical trials on the effect of GLP-1 RAs on fracture risk, which showed that fracture risk was not significantly reduced with use of GLP-1 RA [11, 23]. The gene discussed is GCG; the disease is rheumatoid arthritis.